-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com
Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Rating) in a report released on Friday. The firm set a "sell" rating on the stock.
DBV Technologies Price Performance
DBVT stock opened at $1.41 on Friday. The stock has a market capitalization of $265.15 million, a P/E ratio of -2.56 and a beta of 1.39. The business has a 50-day moving average of $1.48 and a 200-day moving average of $1.98. DBV Technologies has a fifty-two week low of $1.15 and a fifty-two week high of $3.43.
Get DBV Technologies alerts:Hedge Funds Weigh In On DBV Technologies
Large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of DBV Technologies by 16.5% in the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company's stock valued at $1,093,000 after purchasing an additional 97,412 shares during the last quarter. ExodusPoint Capital Management LP bought a new position in shares of DBV Technologies in the 2nd quarter worth about $352,000. BNP Paribas Arbitrage SNC raised its position in shares of DBV Technologies by 203.3% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 57,899 shares of the company's stock worth $102,000 after acquiring an additional 38,812 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in shares of DBV Technologies in the 3rd quarter worth about $67,000. Finally, Two Sigma Investments LP increased its position in DBV Technologies by 80.9% in the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company's stock valued at $64,000 after buying an additional 16,066 shares in the last quarter. Institutional investors own 27.55% of the company's stock.
About DBV Technologies
(Get Rating)DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
Recommended Stories
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Rating) in a report released on Friday. The firm set a "sell" rating on the stock.
斯托克新聞網的股票分析師在週五發佈的一份報告中假設了DBV Technologies(納斯達克代碼:DBVT-GET Rating)的股票。該公司對該股設定了“賣出”評級。
DBV Technologies Price Performance
DBV技術性價比
DBVT stock opened at $1.41 on Friday. The stock has a market capitalization of $265.15 million, a P/E ratio of -2.56 and a beta of 1.39. The business has a 50-day moving average of $1.48 and a 200-day moving average of $1.98. DBV Technologies has a fifty-two week low of $1.15 and a fifty-two week high of $3.43.
DBVT股價上週五開盤報1.41美元。該股市值為2.6515億美元,本益比為-2.56,貝塔係數為1.39。該業務的50日移動均線切入位在1.48美元,200日移動均線切入位在1.98美元。DBV Technologies的股價為52周低點1.15美元,52周高位為3.43美元。
Hedge Funds Weigh In On DBV Technologies
對沖基金看好DBV Technologies
Large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of DBV Technologies by 16.5% in the 1st quarter. BlackRock Inc. now owns 687,341 shares of the company's stock valued at $1,093,000 after purchasing an additional 97,412 shares during the last quarter. ExodusPoint Capital Management LP bought a new position in shares of DBV Technologies in the 2nd quarter worth about $352,000. BNP Paribas Arbitrage SNC raised its position in shares of DBV Technologies by 203.3% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 57,899 shares of the company's stock worth $102,000 after acquiring an additional 38,812 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in shares of DBV Technologies in the 3rd quarter worth about $67,000. Finally, Two Sigma Investments LP increased its position in DBV Technologies by 80.9% in the 3rd quarter. Two Sigma Investments LP now owns 35,920 shares of the company's stock valued at $64,000 after buying an additional 16,066 shares in the last quarter. Institutional investors own 27.55% of the company's stock.
大型投資者最近對他們在該公司的頭寸進行了調整。貝萊德股份有限公司在第一季度增持了DBV科技公司16.5%的股份。貝萊德股份有限公司目前持有該公司687,341股股票,價值1,093,000美元,該公司在上個季度又購買了97,412股。ExodusPoint Capital Management LP在第二季度購買了DBV Technologies的新頭寸,價值約352,000美元。法國巴黎銀行套利SNC在第三季度將其在DBV Technologies的股票頭寸提高了203.3%。法國巴黎銀行套利SNC現在擁有57,899股該公司股票,價值102,000美元,上個季度又收購了38,812股。Envestnet Asset Management Inc.在第三季度購買了DBV Technologies的新頭寸,價值約6.7萬美元。最後,Two Sigma Investments LP在第三季度將其在DBV Technologies的頭寸增加了80.9%。Two Sigma Investments LP現在擁有35,920股該公司股票,價值64,000美元,上個季度又購買了16,066股。機構投資者持有該公司27.55%的股份。
About DBV Technologies
關於DBV技術
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
DBV Technologies SA是一家臨床階段的生物製藥公司,致力於皮膚表面免疫治療產品的研究和開發。它的主要候選產品是Viaskin花生,這是一種免疫療法產品,已經完成了治療4至11歲兒童、青少年和成人花生過敏的第三階段臨床試驗。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- Game-Changing News For Mullen Automotive
- Inflation and the Energy Crisis are Two Freight Trains on a Collision Course – Here's How to Prepare
- Is Enterprise Products Partners Fairly Valued?
- 免費獲取StockNews.com關於DBV技術的研究報告(DBVT)
- 拖拉機庫存能否突破杯柄收購點?
- 現在不是購買Lennar的時候,但時機即將到來
- 馬倫汽車公司改變遊戲規則的消息
- 通貨膨脹和能源危機是兩列相撞的貨運列車--以下是如何做好準備的
- 企業產品合作夥伴是否得到公平評價?
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受DBV技術日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對DBV Technologies和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧